{"disease":{"id":"asthma","name":"Asthma","therapeutic_area":"Respiratory","data":{"aiSummary":"The asthma treatment landscape has evolved significantly with the introduction of biologics targeting specific inflammatory pathways. Current management focuses on inhaled corticosteroids and long-acting beta-agonists, with add-on therapies like anti-IgE and anti-IL-5 agents for severe cases. Recent advances include the development of novel biologics and improved inhaler devices. The pipeline includes new formulations and targeted therapies, aiming to improve asthma control and reduce exacerbations.","drug_count":6,"description":"Asthma is a chronic inflammatory disease of the airways characterized by reversible airflow obstruction, bronchial hyperresponsiveness, and underlying inflammation. This leads to recurrent episodes of wheezing, breathlessness, chest tightness, and coughing, particularly at night or in the early morning. The pathophysiology involves complex interactions of inflammatory cells, mediators, and structural changes in the airways, resulting in airway narrowing and increased mucus production.","subtype_count":13},"enrichment_level":2,"last_enriched_at":null,"visit_count":0,"created_at":"2026-03-25T12:16:34.909Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":56,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"dupilumab","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dupixent","generic_name":"DUPILUMAB","company_name":"Regeneron","drug_phase":"marketed","molecular_target":"Interleukin-4 receptor subunit alpha","drug_class":"Interleukin-4 Receptor alpha Antagonist [EPC]","quality_score":62,"revenue":"14600","mechanism":"Dupixent blocks the interleukin-4 receptor, a key player in the immune system's inflammatory response."},{"drug_id":"omalizumab","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xolair","generic_name":"omalizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Ig epsilon chain C region","drug_class":"Anti-IgE [EPC]","quality_score":52,"revenue":"3200","mechanism":null},{"drug_id":"vilanterol","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Breo Ellipta","generic_name":"VILANTEROL","company_name":"Glaxo Grp Ltd","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"beta2-Adrenergic Agonist","quality_score":60,"revenue":"3100","mechanism":"Breo Ellipta works by stimulating the beta-2 adrenergic receptor to relax airway muscles and improve breathing."},{"drug_id":"umeclidinium","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Incruse Ellipta","generic_name":"UMECLIDINIUM","company_name":"Glaxo Grp England","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M4","drug_class":"Anticholinergic","quality_score":70,"revenue":"3100","mechanism":"Umeclidinium works by blocking the M4 muscarinic acetylcholine receptor to relax airway smooth muscle and improve breathing."},{"drug_id":"fluticasone-furoate","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arnuity Ellipta","generic_name":"FLUTICASONE FUROATE","company_name":"Haleon Us Holdings","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":62,"revenue":"3100","mechanism":""},{"drug_id":"desonide","indication_name":"Asthma management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Verdeso","generic_name":"DESONIDE","company_name":"Padagis Us","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":50,"revenue":"2800","mechanism":""},{"drug_id":"desonide","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Verdeso","generic_name":"DESONIDE","company_name":"Padagis Us","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":50,"revenue":"2800","mechanism":""},{"drug_id":"budesonide","indication_name":"Asthma management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pulmicort Respules","generic_name":"BUDESONIDE","company_name":"AstraZeneca K.K.","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":64,"revenue":"2800","mechanism":""},{"drug_id":"budesonide","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pulmicort Respules","generic_name":"BUDESONIDE","company_name":"AstraZeneca K.K.","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":64,"revenue":"2800","mechanism":""},{"drug_id":"tiotropium-bromide","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Spiriva","generic_name":"TIOTROPIUM BROMIDE","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M3","drug_class":"Anticholinergic","quality_score":75,"revenue":"2500","mechanism":"Spiriva works by blocking the action of a chemical called acetylcholine, which causes airway muscles to contract and narrow the airways."},{"drug_id":"benralizumab","indication_name":"Eosinophilic asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fasenra","generic_name":"BENRALIZUMAB","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Interleukin-5 receptor subunit alpha","drug_class":"Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC]","quality_score":66,"revenue":"1800","mechanism":"Fasenra works by binding to the interleukin-5 receptor on eosinophils, triggering their destruction."},{"drug_id":"mepolizumab","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nucala","generic_name":"MEPOLIZUMAB","company_name":"GSK","drug_phase":"marketed","molecular_target":"Interleukin-5","drug_class":"Interleukin-5 Antagonist [EPC]","quality_score":70,"revenue":"1600","mechanism":"Nucala works by binding to interleukin-5, a protein that stimulates the production of eosinophils."},{"drug_id":"mepolizumab","indication_name":"Eosinophilic asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nucala","generic_name":"MEPOLIZUMAB","company_name":"GSK","drug_phase":"marketed","molecular_target":"Interleukin-5","drug_class":"Interleukin-5 Antagonist [EPC]","quality_score":70,"revenue":"1600","mechanism":"Nucala works by binding to interleukin-5, a protein that stimulates the production of eosinophils."},{"drug_id":"amg-157","indication_name":"Severe asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tezspire","generic_name":"AMG 157","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Thymic stromal lymphopoietin","drug_class":"Thymic Stromal Lymphopoietin Blocker [EPC]","quality_score":66,"revenue":"800","mechanism":"Tezspire blocks the action of Thymic Stromal Lymphopoietin (TSLP), a protein that triggers inflammation in the airways."},{"drug_id":"fluticasone-propionate","indication_name":"Non-allergic asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cutivate","generic_name":"FLUTICASONE PROPIONATE","company_name":"Teva Pharm","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":64,"revenue":"69.0","mechanism":""},{"drug_id":"fluticasone-propionate","indication_name":"Asthma management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cutivate","generic_name":"FLUTICASONE PROPIONATE","company_name":"Teva Pharm","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":64,"revenue":"69.0","mechanism":""},{"drug_id":"fluticasone-propionate","indication_name":"Allergic asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cutivate","generic_name":"FLUTICASONE PROPIONATE","company_name":"Teva Pharm","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":64,"revenue":"69.0","mechanism":""},{"drug_id":"hydrocortisone-acetate","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortifoam","generic_name":"HYDROCORTISONE ACETATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"formoterol","indication_name":"Adjunct Therapy to Achieve Long-term Asthma Control","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Foradil","generic_name":"FORMOTEROL","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"beta2-Adrenergic Agonist","quality_score":56,"revenue":null,"mechanism":"Foradil works by stimulating the beta-2 adrenergic receptor to relax airway muscles and improve breathing."},{"drug_id":"formoterol","indication_name":"Allergic asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Foradil","generic_name":"FORMOTEROL","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"beta2-Adrenergic Agonist","quality_score":56,"revenue":null,"mechanism":"Foradil works by stimulating the beta-2 adrenergic receptor to relax airway muscles and improve breathing."},{"drug_id":"formoterol","indication_name":"Non-allergic asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Foradil","generic_name":"FORMOTEROL","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"beta2-Adrenergic Agonist","quality_score":56,"revenue":null,"mechanism":"Foradil works by stimulating the beta-2 adrenergic receptor to relax airway muscles and improve breathing."},{"drug_id":"alvesco","indication_name":"Asthma management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Omnaris","generic_name":"Alvesco","company_name":"Takeda Gmbh","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"ciclesonide","quality_score":63,"revenue":null,"mechanism":"Omnaris works by activating the glucocorticoid receptor to reduce inflammation in the airways."},{"drug_id":"nedocromil","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alocril","generic_name":"NEDOCROMIL","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"G-protein coupled receptor 35","drug_class":"Mast Cell Stabilizer","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"nedocromil","indication_name":"Asthma management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alocril","generic_name":"NEDOCROMIL","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"G-protein coupled receptor 35","drug_class":"Mast Cell Stabilizer","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"cortisone-acetate","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortone","generic_name":"CORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"ciclesonide","indication_name":"Asthma management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Omnaris","generic_name":"CICLESONIDE","company_name":"Covis","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"ciclesonide","quality_score":63,"revenue":null,"mechanism":"Omnaris works by binding to the glucocorticoid receptor, which then reduces inflammation in the airways."},{"drug_id":"salbutamol","indication_name":"Acute exacerbation of asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Proventil","generic_name":"salbutamol","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"beta2-Adrenergic Agonist","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"beclomethasone","indication_name":"maintenance treatment of asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Qvar Redihaler","generic_name":"BECLOMETHASONE","company_name":"Norton Waterford","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"cromoglicic-acid","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Intal","generic_name":"cromoglicic acid","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"G-protein coupled receptor 35","drug_class":"Mast Cell Stabilizer","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"cromoglicic-acid","indication_name":"Asthma management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Intal","generic_name":"cromoglicic acid","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"G-protein coupled receptor 35","drug_class":"Mast Cell Stabilizer","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"flovent-500mcg","indication_name":"Maintenance treatment of asthma as prophylactic therapy in patients aged 4 years and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FLOVENT 500mcg","company_name":"GlaxoSmithKline","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor (GR)","drug_class":"Inhaled corticosteroid (ICS)","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"betamethasone-acetate","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Celestone Soluspan","generic_name":"BETAMETHASONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone","indication_name":"Exacerbation of asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"fluticasone","indication_name":"Allergic asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Flonase","generic_name":"fluticasone propionate","company_name":"GSK (GlaxoSmithKline)","drug_phase":"marketed","molecular_target":"Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Inhaled/intranasal corticosteroid","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"fluticasone","indication_name":"Asthma management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Flonase","generic_name":"fluticasone propionate","company_name":"GSK (GlaxoSmithKline)","drug_phase":"marketed","molecular_target":"Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Inhaled/intranasal corticosteroid","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"fluticasone","indication_name":"Non-allergic asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Flonase","generic_name":"fluticasone propionate","company_name":"GSK (GlaxoSmithKline)","drug_phase":"marketed","molecular_target":"Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Inhaled/intranasal corticosteroid","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"albuterol","indication_name":"Acute exacerbation of asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ProAir","generic_name":"albuterol","company_name":"Generic (originally Allen & Hanburys/GSK)","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Beta-2 adrenergic receptor","drug_class":"SABA (Short-acting beta-2 agonist)","quality_score":56,"revenue":null,"mechanism":"Short-acting beta-2 adrenergic agonist (SABA) that relaxes bronchial smooth muscle, providing rapid relief of bronchospasm."},{"drug_id":"indacaterol","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arcapta Neohaler","generic_name":"INDACATEROL","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"beta2-Adrenergic Agonist","quality_score":38,"revenue":null,"mechanism":""},{"drug_id":"cromoglicate","indication_name":"Asthma management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cromoglicate","company_name":"LEO Pharma","drug_phase":"discontinued","molecular_target":"Protein S100-P, G-protein coupled receptor 35, Taste receptor type 2 member 20","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"beclometasone-dipropionate","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Beconase Aq","generic_name":"beclometasone dipropionate","company_name":"","drug_phase":"marketed","molecular_target":"Probable G-protein coupled receptor 97","drug_class":"Corticosteroid","quality_score":51,"revenue":null,"mechanism":""},{"drug_id":"beclometasone-dipropionate","indication_name":"Asthma management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Beconase Aq","generic_name":"beclometasone dipropionate","company_name":"","drug_phase":"marketed","molecular_target":"Probable G-protein coupled receptor 97","drug_class":"Corticosteroid","quality_score":51,"revenue":null,"mechanism":""},{"drug_id":"flixotide","indication_name":"Allergic asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Flixotide","company_name":"Mundipharma Research Limited","drug_phase":"marketed","molecular_target":"Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"flixotide","indication_name":"Asthma management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Flixotide","company_name":"Mundipharma Research Limited","drug_phase":"marketed","molecular_target":"Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"methacholine","indication_name":"Diagnostic Test for Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Provocholine","generic_name":"METHACHOLINE","company_name":"Methapharm","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"Cholinergic Receptor Agonist","quality_score":60,"revenue":null,"mechanism":"Provocholine works by stimulating the M1 muscarinic acetylcholine receptor."},{"drug_id":"rhinocort","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rhinocort","company_name":"Marinomed Biotech AG","drug_phase":"marketed","molecular_target":"Matrix metalloproteinase-9, Probable G-protein coupled receptor 97, Glucocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"rhinocort","indication_name":"Asthma management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rhinocort","company_name":"Marinomed Biotech AG","drug_phase":"marketed","molecular_target":"Matrix metalloproteinase-9, Probable G-protein coupled receptor 97, Glucocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"prednison","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednison","company_name":"Wen Zhang","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"prednison","indication_name":"Exacerbation of asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednison","company_name":"Wen Zhang","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"singulair","indication_name":"Allergic asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Singulair","company_name":"Genuine Research Center, Egypt","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C8, Adenosine receptor A3, Cysteinyl leukotriene receptor 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"singulair","indication_name":"Asthma management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Singulair","company_name":"Genuine Research Center, Egypt","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C8, Adenosine receptor A3, Cysteinyl leukotriene receptor 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"singulair","indication_name":"Non-allergic asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Singulair","company_name":"Genuine Research Center, Egypt","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C8, Adenosine receptor A3, Cysteinyl leukotriene receptor 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"nasonex","indication_name":"Allergic asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nasonex","company_name":"University of Alberta","drug_phase":"marketed","molecular_target":"Multidrug resistance protein 1, Glucocorticoid receptor, Progesterone receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"nasonex","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nasonex","company_name":"University of Alberta","drug_phase":"marketed","molecular_target":"Multidrug resistance protein 1, Glucocorticoid receptor, Progesterone receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"nasonex","indication_name":"Asthma management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nasonex","company_name":"University of Alberta","drug_phase":"marketed","molecular_target":"Multidrug resistance protein 1, Glucocorticoid receptor, Progesterone receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"nasonex","indication_name":"Non-allergic asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nasonex","company_name":"University of Alberta","drug_phase":"marketed","molecular_target":"Multidrug resistance protein 1, Glucocorticoid receptor, Progesterone receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"tezepelumab-ekko","indication_name":"Severe asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TEZSPIRE","generic_name":"TEZEPELUMAB-EKKO","company_name":"ASTRAZENECA AB","drug_phase":"marketed","molecular_target":"Thymic stromal lymphopoietin","drug_class":"Thymic Stromal Lymphopoietin Blocker [EPC]","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"methylprednisolone","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Medrol","generic_name":"methylprednisolone","company_name":"Generic (originally Upjohn/Pfizer)","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"Glucocorticoid (corticosteroid)","quality_score":62,"revenue":null,"mechanism":"Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions."},{"drug_id":"methylprednisolone","indication_name":"Exacerbation of asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Medrol","generic_name":"methylprednisolone","company_name":"Generic (originally Upjohn/Pfizer)","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"Glucocorticoid (corticosteroid)","quality_score":62,"revenue":null,"mechanism":"Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions."},{"drug_id":"hydrocortisone","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortef","generic_name":"hydrocortisone","company_name":"Generic (originally Merck/Upjohn)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"Corticosteroid [EPC]","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"ethylnorepinephrine","indication_name":"Acute exacerbation of asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Butanefrine","generic_name":"ethylnorepinephrine","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Butanefrine works by stimulating the body's natural responses to constrict blood vessels and increase airway resistance."},{"drug_id":"ethylnorepinephrine","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Butanefrine","generic_name":"ethylnorepinephrine","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Butanefrine works by stimulating the body's natural responses to constrict blood vessels and increase airway resistance."},{"drug_id":"ethylnorepinephrine","indication_name":"Asthma management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Butanefrine","generic_name":"ethylnorepinephrine","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Butanefrine works by stimulating the body's natural responses to constrict blood vessels and increase airway resistance."},{"drug_id":"acefylline","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Acephylline","generic_name":"ACEFYLLINE","company_name":"","drug_phase":"phase_2","molecular_target":"Adenosine receptor A2b","drug_class":"acefylline","quality_score":null,"revenue":null,"mechanism":"Acephylline works by binding to the adenosine receptor A2b, which helps to relax airway smooth muscle and improve lung function."},{"drug_id":"triamcinolone","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":51,"revenue":null,"mechanism":""},{"drug_id":"triamcinolone","indication_name":"Asthma management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":51,"revenue":null,"mechanism":""},{"drug_id":"xolair","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xolair","company_name":"Taizhou Mabtech Pharmaceutical Co.,Ltd","drug_phase":"marketed","molecular_target":"Ig epsilon chain C region","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"flixotide","indication_name":"Non-allergic asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Flixotide","company_name":"Mundipharma Research Limited","drug_phase":"marketed","molecular_target":"Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"fluticason","indication_name":"Allergic asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fluticason","company_name":"Creighton University","drug_phase":"marketed","molecular_target":"Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"fluticason","indication_name":"Asthma management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fluticason","company_name":"Creighton University","drug_phase":"marketed","molecular_target":"Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"fluticason","indication_name":"Non-allergic asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fluticason","company_name":"Creighton University","drug_phase":"marketed","molecular_target":"Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"levalbuterol","indication_name":"Acute exacerbation of asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Levalbuterol","company_name":"University of Aleppo","drug_phase":"marketed","molecular_target":"beta 2 -adrenergic receptors","drug_class":"","quality_score":52,"revenue":null,"mechanism":"Levalbuterol activates beta 2 -adrenergic receptors, increasing cyclic AMP and relaxing airway smooth muscles."},{"drug_id":"prednisone","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"prednisone","indication_name":"Exacerbation of asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"theophyllin","indication_name":"Acute exacerbation of asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Theophyllin","company_name":"University of Bergen","drug_phase":"marketed","molecular_target":"Adenosine receptor A3, Alkaline phosphatase, tissue-nonspecific isozyme, Adenosine receptor A1","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"theophyllin","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Theophyllin","company_name":"University of Bergen","drug_phase":"marketed","molecular_target":"Adenosine receptor A3, Alkaline phosphatase, tissue-nonspecific isozyme, Adenosine receptor A1","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"theophyllin","indication_name":"Asthma management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Theophyllin","company_name":"University of Bergen","drug_phase":"marketed","molecular_target":"Adenosine receptor A3, Alkaline phosphatase, tissue-nonspecific isozyme, Adenosine receptor A1","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"theophyllin","indication_name":"Asthma night-time symptoms","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Theophyllin","company_name":"University of Bergen","drug_phase":"marketed","molecular_target":"Adenosine receptor A3, Alkaline phosphatase, tissue-nonspecific isozyme, Adenosine receptor A1","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"theophyllin","indication_name":"Asthma-chronic obstructive pulmonary disease overlap syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Theophyllin","company_name":"University of Bergen","drug_phase":"marketed","molecular_target":"Adenosine receptor A3, Alkaline phosphatase, tissue-nonspecific isozyme, Adenosine receptor A1","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"epinephrine","indication_name":"Acute exacerbation of asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epipen","generic_name":"epinephrine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Alpha-1D adrenergic receptor","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":80,"revenue":null,"mechanism":"Epipen works by stimulating the alpha-1D adrenergic receptor to rapidly increase heart rate, blood pressure, and bronchodilation."},{"drug_id":"epinephrine","indication_name":"Asthma management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epipen","generic_name":"epinephrine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Alpha-1D adrenergic receptor","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":80,"revenue":null,"mechanism":"Epipen works by stimulating the alpha-1D adrenergic receptor to rapidly increase heart rate, blood pressure, and bronchodilation."},{"drug_id":"epinephrine","indication_name":"Exacerbation of asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epipen","generic_name":"epinephrine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Alpha-1D adrenergic receptor","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":80,"revenue":null,"mechanism":"Epipen works by stimulating the alpha-1D adrenergic receptor to rapidly increase heart rate, blood pressure, and bronchodilation."},{"drug_id":"norepinephrine","indication_name":"Acute exacerbation of asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norepinephrine Bitartrate In 5% Dextrose","generic_name":"NOREPINEPHRINE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"alpha-adrenergic receptors, beta-adrenergic receptors","drug_class":"Catecholamine","quality_score":80,"revenue":null,"mechanism":"Norepinephrine constricts blood vessels and stimulates the heart."},{"drug_id":"norepinephrine","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norepinephrine Bitartrate In 5% Dextrose","generic_name":"NOREPINEPHRINE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"alpha-adrenergic receptors, beta-adrenergic receptors","drug_class":"Catecholamine","quality_score":80,"revenue":null,"mechanism":"Norepinephrine constricts blood vessels and stimulates the heart."},{"drug_id":"norepinephrine","indication_name":"Asthma management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norepinephrine Bitartrate In 5% Dextrose","generic_name":"NOREPINEPHRINE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"alpha-adrenergic receptors, beta-adrenergic receptors","drug_class":"Catecholamine","quality_score":80,"revenue":null,"mechanism":"Norepinephrine constricts blood vessels and stimulates the heart."},{"drug_id":"flunisolide","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aerospan Hfa","generic_name":"FLUNISOLIDE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"flunisolide","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"flunisolide","indication_name":"Asthma management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aerospan Hfa","generic_name":"FLUNISOLIDE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"flunisolide","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"ephedrine-hydrochloride-3-mg-ml","indication_name":"Treatment of bronchial asthma, transient or intermittent in nature, when oral therapy is not appropriate","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ephedrine Hydrochloride 3 MG/ML","company_name":"University Hospital, Ghent","drug_phase":"marketed","molecular_target":"α-adrenergic receptors (α1, α2) and β-adrenergic receptors (β1, β2); sympathetic nerve terminals","drug_class":"Sympathomimetic amine; adrenergic agonist","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"oxymorphone","indication_name":"Anxiety due to Cardiac Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opana Er","generic_name":"OXYMORPHONE","company_name":"Endo","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Agonist","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"levosalbutamol","indication_name":"Acute exacerbation of asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xopenex","generic_name":"LEVOSALBUTAMOL","company_name":"Oak Pharms Inc","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"beta2-Adrenergic Agonist","quality_score":65,"revenue":null,"mechanism":"Xopenex works by activating the beta-2 adrenergic receptor, leading to bronchodilation and relaxation of airway smooth muscle."},{"drug_id":"lidocaine-hydrochloride-and-epinephrine","indication_name":"Acute exacerbation of asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bupivacaine Hydrochloride And Epinephrine","generic_name":"Epinephrine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Alpha-1D adrenergic receptor","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":80,"revenue":null,"mechanism":"Epinephrine works by stimulating the alpha-1D adrenergic receptor to increase heart rate and blood pressure, and to constrict blood vessels."},{"drug_id":"lidocaine-hydrochloride-and-epinephrine","indication_name":"Asthma management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bupivacaine Hydrochloride And Epinephrine","generic_name":"Epinephrine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Alpha-1D adrenergic receptor","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":80,"revenue":null,"mechanism":"Epinephrine works by stimulating the alpha-1D adrenergic receptor to increase heart rate and blood pressure, and to constrict blood vessels."},{"drug_id":"lidocaine-hydrochloride-and-epinephrine","indication_name":"Exacerbation of asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bupivacaine Hydrochloride And Epinephrine","generic_name":"Epinephrine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Alpha-1D adrenergic receptor","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":80,"revenue":null,"mechanism":"Epinephrine works by stimulating the alpha-1D adrenergic receptor to increase heart rate and blood pressure, and to constrict blood vessels."},{"drug_id":"ppsv23","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae in adults 2 years of age or older with chronic lung disease, including chronic obstructive pulmonary disease (COPD) and asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ppsv23","generic_name":"ppsv23","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"diprophylline","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diphyllin","generic_name":"diprophylline","company_name":"","drug_phase":"marketed","molecular_target":"cAMP-specific 3',5'-cyclic phosphodiesterase 4B","drug_class":"diprophylline","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"diprophylline","indication_name":"Asthma management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diphyllin","generic_name":"diprophylline","company_name":"","drug_phase":"marketed","molecular_target":"cAMP-specific 3',5'-cyclic phosphodiesterase 4B","drug_class":"diprophylline","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"diprophylline","indication_name":"Asthma night-time symptoms","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diphyllin","generic_name":"diprophylline","company_name":"","drug_phase":"marketed","molecular_target":"cAMP-specific 3',5'-cyclic phosphodiesterase 4B","drug_class":"diprophylline","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"diprophylline","indication_name":"Asthma-chronic obstructive pulmonary disease overlap syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diphyllin","generic_name":"diprophylline","company_name":"","drug_phase":"marketed","molecular_target":"cAMP-specific 3',5'-cyclic phosphodiesterase 4B","drug_class":"diprophylline","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"orciprenaline","indication_name":"Acute exacerbation of asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Metaproterenol","generic_name":"orciprenaline","company_name":"","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"beta2-Adrenergic Agonist","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"orciprenaline","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Metaproterenol","generic_name":"orciprenaline","company_name":"","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"beta2-Adrenergic Agonist","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"orciprenaline","indication_name":"Asthma management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Metaproterenol","generic_name":"orciprenaline","company_name":"","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"beta2-Adrenergic Agonist","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"mometasone-furoate","indication_name":"Allergic asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Elocon","generic_name":"MOMETASONE FUROATE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Progesterone receptor","drug_class":"Corticosteroid","quality_score":75,"revenue":null,"mechanism":"Elocon works by binding to the progesterone receptor, which reduces inflammation and immune response in the body."},{"drug_id":"mometasone-furoate","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Elocon","generic_name":"MOMETASONE FUROATE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Progesterone receptor","drug_class":"Corticosteroid","quality_score":75,"revenue":null,"mechanism":"Elocon works by binding to the progesterone receptor, which reduces inflammation and immune response in the body."},{"drug_id":"mometasone-furoate","indication_name":"Asthma management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Elocon","generic_name":"MOMETASONE FUROATE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Progesterone receptor","drug_class":"Corticosteroid","quality_score":75,"revenue":null,"mechanism":"Elocon works by binding to the progesterone receptor, which reduces inflammation and immune response in the body."},{"drug_id":"mometasone-furoate","indication_name":"Non-allergic asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Elocon","generic_name":"MOMETASONE FUROATE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Progesterone receptor","drug_class":"Corticosteroid","quality_score":75,"revenue":null,"mechanism":"Elocon works by binding to the progesterone receptor, which reduces inflammation and immune response in the body."},{"drug_id":"diethylcarbamazine","indication_name":"Eosinophilic asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Caricide","generic_name":"DIETHYLCARBAMAZINE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Arachidonate 5-lipoxygenase","drug_class":"Anthelmintic","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pranlukast","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Onon","generic_name":"PRANLUKAST","company_name":"","drug_phase":"marketed","molecular_target":"Cysteinyl leukotriene receptor 1","drug_class":"pranlukast","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"terbutaline","indication_name":"Acute exacerbation of asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Brethine","generic_name":"TERBUTALINE","company_name":"","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"terbutaline","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"terbutaline","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Brethine","generic_name":"TERBUTALINE","company_name":"","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"terbutaline","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"terbutaline","indication_name":"Asthma management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Brethine","generic_name":"TERBUTALINE","company_name":"","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"terbutaline","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"reslizumab","indication_name":"Eosinophilic asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cinqair","generic_name":"RESLIZUMAB","company_name":"Teva Respiratory Llc","drug_phase":"marketed","molecular_target":"Interleukin-5","drug_class":"Interleukin-5 Antagonist [EPC]","quality_score":55,"revenue":null,"mechanism":"Cinqair works by blocking the action of interleukin-5, a protein that promotes the production of eosinophils, which contribute to inflammation in the airways."},{"drug_id":"zafirlukast","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Accolate","generic_name":"ZAFIRLUKAST","company_name":"Strides Pharma Intl","drug_phase":"marketed","molecular_target":"Cysteinyl leukotriene receptor 1","drug_class":"Leukotriene Receptor Antagonist [EPC]","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"zafirlukast","indication_name":"Asthma management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Accolate","generic_name":"ZAFIRLUKAST","company_name":"Strides Pharma Intl","drug_phase":"marketed","molecular_target":"Cysteinyl leukotriene receptor 1","drug_class":"Leukotriene Receptor Antagonist [EPC]","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"betamethasone","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betametasone","generic_name":"BETAMETHASONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system."},{"drug_id":"bitolterol","indication_name":"Acute exacerbation of asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tornalate","generic_name":"BITOLTEROL","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"bitolterol","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"bitolterol","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tornalate","generic_name":"BITOLTEROL","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"bitolterol","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"bitolterol","indication_name":"Asthma management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tornalate","generic_name":"BITOLTEROL","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"bitolterol","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"tezspire","indication_name":"Severe asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Tezspire","company_name":"Qilu Pharmaceutical Co., Ltd.","drug_phase":"marketed","molecular_target":"Thymic stromal lymphopoietin","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"beclometasone","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Beclometasone","company_name":"Imperial College London","drug_phase":"marketed","molecular_target":"Matrix metalloproteinase-9, Probable G-protein coupled receptor 97, Glucocorticoid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"beclometasone","indication_name":"Asthma management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Beclometasone","company_name":"Imperial College London","drug_phase":"marketed","molecular_target":"Matrix metalloproteinase-9, Probable G-protein coupled receptor 97, Glucocorticoid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"incruse","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Incruse","company_name":"Fundacio Privada Mon Clinic Barcelona","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"serevent","indication_name":"Adjunct Therapy to Achieve Long-term Asthma Control","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Serevent","company_name":"Fundacio Privada Mon Clinic Barcelona","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"serevent","indication_name":"Allergic asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Serevent","company_name":"Fundacio Privada Mon Clinic Barcelona","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"serevent","indication_name":"Non-allergic asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Serevent","company_name":"Fundacio Privada Mon Clinic Barcelona","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolone","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"prednisolone","indication_name":"Eosinophilic asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"prednisolone","indication_name":"Exacerbation of asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"epinephrin","indication_name":"Acute exacerbation of asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Epinephrin","company_name":"United States Naval Medical Center, San Diego","drug_phase":"marketed","molecular_target":"Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"epinephrin","indication_name":"Asthma management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Epinephrin","company_name":"United States Naval Medical Center, San Diego","drug_phase":"marketed","molecular_target":"Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"epinephrin","indication_name":"Exacerbation of asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Epinephrin","company_name":"United States Naval Medical Center, San Diego","drug_phase":"marketed","molecular_target":"Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolon","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolon","indication_name":"Eosinophilic asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolon","indication_name":"Exacerbation of asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"nucala","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nucala","company_name":"Mayo Clinic","drug_phase":"marketed","molecular_target":"Interleukin-5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"nucala","indication_name":"Eosinophilic asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nucala","company_name":"Mayo Clinic","drug_phase":"marketed","molecular_target":"Interleukin-5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolon","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methylprednisolon","company_name":"Leiden University Medical Center","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolon","indication_name":"Exacerbation of asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methylprednisolon","company_name":"Leiden University Medical Center","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"aminophyllin","indication_name":"Acute exacerbation of asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Aminophyllin","company_name":"University of Padova","drug_phase":"marketed","molecular_target":"Adenosine receptor A3, Alkaline phosphatase, tissue-nonspecific isozyme, Adenosine receptor A1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"aminophyllin","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Aminophyllin","company_name":"University of Padova","drug_phase":"marketed","molecular_target":"Adenosine receptor A3, Alkaline phosphatase, tissue-nonspecific isozyme, Adenosine receptor A1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"aminophyllin","indication_name":"Asthma management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Aminophyllin","company_name":"University of Padova","drug_phase":"marketed","molecular_target":"Adenosine receptor A3, Alkaline phosphatase, tissue-nonspecific isozyme, Adenosine receptor A1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"aminophyllin","indication_name":"Asthma night-time symptoms","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Aminophyllin","company_name":"University of Padova","drug_phase":"marketed","molecular_target":"Adenosine receptor A3, Alkaline phosphatase, tissue-nonspecific isozyme, Adenosine receptor A1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"aminophyllin","indication_name":"Asthma-chronic obstructive pulmonary disease overlap syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Aminophyllin","company_name":"University of Padova","drug_phase":"marketed","molecular_target":"Adenosine receptor A3, Alkaline phosphatase, tissue-nonspecific isozyme, Adenosine receptor A1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"xopenex","indication_name":"Acute exacerbation of asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"xopenex","company_name":"Phoenix Children's Hospital","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"noradrenaline","indication_name":"Acute exacerbation of asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Noradrenaline","company_name":"Tanta University","drug_phase":"marketed","molecular_target":"Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"noradrenaline","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Noradrenaline","company_name":"Tanta University","drug_phase":"marketed","molecular_target":"Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"noradrenaline","indication_name":"Asthma management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Noradrenaline","company_name":"Tanta University","drug_phase":"marketed","molecular_target":"Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cromoglycate","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cromoglycate","company_name":"Vishwajit Nimgaonkar, MD PhD","drug_phase":"phase_3","molecular_target":"Protein S100-P, G-protein coupled receptor 35, Taste receptor type 2 member 20","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cromoglycate","indication_name":"Asthma management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cromoglycate","company_name":"Vishwajit Nimgaonkar, MD PhD","drug_phase":"phase_3","molecular_target":"Protein S100-P, G-protein coupled receptor 35, Taste receptor type 2 member 20","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"montelukast","indication_name":"Allergic asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Singulair","generic_name":"montelukast","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C8, Adenosine receptor A3, Cysteinyl leukotriene receptor 2","drug_class":"Leukotriene receptor antagonist (LTRA)","quality_score":null,"revenue":null,"mechanism":"Leukotriene receptor antagonist (LTRA) that blocks CysLT1 receptors, reducing bronchoconstriction, mucus production, and airway inflammation."},{"drug_id":"montelukast","indication_name":"Asthma management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Singulair","generic_name":"montelukast","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C8, Adenosine receptor A3, Cysteinyl leukotriene receptor 2","drug_class":"Leukotriene receptor antagonist (LTRA)","quality_score":null,"revenue":null,"mechanism":"Leukotriene receptor antagonist (LTRA) that blocks CysLT1 receptors, reducing bronchoconstriction, mucus production, and airway inflammation."},{"drug_id":"montelukast","indication_name":"Non-allergic asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Singulair","generic_name":"montelukast","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C8, Adenosine receptor A3, Cysteinyl leukotriene receptor 2","drug_class":"Leukotriene receptor antagonist (LTRA)","quality_score":null,"revenue":null,"mechanism":"Leukotriene receptor antagonist (LTRA) that blocks CysLT1 receptors, reducing bronchoconstriction, mucus production, and airway inflammation."},{"drug_id":"mometasone","indication_name":"Allergic asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MOMETASONE","company_name":"","drug_phase":"discontinued","molecular_target":"Multidrug resistance protein 1, Glucocorticoid receptor, Progesterone receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":"12.1 Mechanism of Action Mometasone furoate nasal spray is a corticosteroid demonstrating potent anti-inflammatory properties. The precise mechanism of corticosteroid action on allergic rhinitis is not known. Corticosteroids have been shown to have a wide range of effects on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in inflammation. In two clinical studies utilizing nasal antigen challenge, mometasone furoate nasal spray decreased some markers of the early- and late-phase allergic response. These observations included decreases (vs. placebo) in histamine and eosinophil cationic protein levels, and reductions (vs. baseline) in eosinophils, neutrophils, and epithelial cell adhesion proteins. The clinical significance of these findings is not known. The effect of mometasone furoate nasal spray on nasal mucosa following 12 months of treatment was examined in 46 patients with allergic rhinitis. There was no evidence of atrophy and there was a marked reduction in intraepithelial eosinophilia and inflammatory cell infiltration (e.g., eosinophils, lymphocytes, monocytes, neutrophils, and plasma cells)."},{"drug_id":"mometasone","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MOMETASONE","company_name":"","drug_phase":"discontinued","molecular_target":"Multidrug resistance protein 1, Glucocorticoid receptor, Progesterone receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":"12.1 Mechanism of Action Mometasone furoate nasal spray is a corticosteroid demonstrating potent anti-inflammatory properties. The precise mechanism of corticosteroid action on allergic rhinitis is not known. Corticosteroids have been shown to have a wide range of effects on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in inflammation. In two clinical studies utilizing nasal antigen challenge, mometasone furoate nasal spray decreased some markers of the early- and late-phase allergic response. These observations included decreases (vs. placebo) in histamine and eosinophil cationic protein levels, and reductions (vs. baseline) in eosinophils, neutrophils, and epithelial cell adhesion proteins. The clinical significance of these findings is not known. The effect of mometasone furoate nasal spray on nasal mucosa following 12 months of treatment was examined in 46 patients with allergic rhinitis. There was no evidence of atrophy and there was a marked reduction in intraepithelial eosinophilia and inflammatory cell infiltration (e.g., eosinophils, lymphocytes, monocytes, neutrophils, and plasma cells)."},{"drug_id":"mometasone","indication_name":"Asthma management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MOMETASONE","company_name":"","drug_phase":"discontinued","molecular_target":"Multidrug resistance protein 1, Glucocorticoid receptor, Progesterone receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":"12.1 Mechanism of Action Mometasone furoate nasal spray is a corticosteroid demonstrating potent anti-inflammatory properties. The precise mechanism of corticosteroid action on allergic rhinitis is not known. Corticosteroids have been shown to have a wide range of effects on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in inflammation. In two clinical studies utilizing nasal antigen challenge, mometasone furoate nasal spray decreased some markers of the early- and late-phase allergic response. These observations included decreases (vs. placebo) in histamine and eosinophil cationic protein levels, and reductions (vs. baseline) in eosinophils, neutrophils, and epithelial cell adhesion proteins. The clinical significance of these findings is not known. The effect of mometasone furoate nasal spray on nasal mucosa following 12 months of treatment was examined in 46 patients with allergic rhinitis. There was no evidence of atrophy and there was a marked reduction in intraepithelial eosinophilia and inflammatory cell infiltration (e.g., eosinophils, lymphocytes, monocytes, neutrophils, and plasma cells)."},{"drug_id":"prednisone","indication_name":"Bronchial asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"mometasone","indication_name":"Non-allergic asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MOMETASONE","company_name":"","drug_phase":"discontinued","molecular_target":"Multidrug resistance protein 1, Glucocorticoid receptor, Progesterone receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":"12.1 Mechanism of Action Mometasone furoate nasal spray is a corticosteroid demonstrating potent anti-inflammatory properties. The precise mechanism of corticosteroid action on allergic rhinitis is not known. Corticosteroids have been shown to have a wide range of effects on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in inflammation. In two clinical studies utilizing nasal antigen challenge, mometasone furoate nasal spray decreased some markers of the early- and late-phase allergic response. These observations included decreases (vs. placebo) in histamine and eosinophil cationic protein levels, and reductions (vs. baseline) in eosinophils, neutrophils, and epithelial cell adhesion proteins. The clinical significance of these findings is not known. The effect of mometasone furoate nasal spray on nasal mucosa following 12 months of treatment was examined in 46 patients with allergic rhinitis. There was no evidence of atrophy and there was a marked reduction in intraepithelial eosinophilia and inflammatory cell infiltration (e.g., eosinophils, lymphocytes, monocytes, neutrophils, and plasma cells)."},{"drug_id":"dexamethasone-phosphate","indication_name":"Bronchial asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexamethasone Sodium Phosphate","generic_name":"dexamethasone phosphate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Androgen receptor, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"salmeterol-xinafoate","indication_name":"Treatment of Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SALMETEROL XINAFOATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":18,"revenue":null,"mechanism":null},{"drug_id":"budesonide-and-formoterol","indication_name":"Treatment of Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"budesonide and formoterol","company_name":"National Jewish Health","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor, beta 2 -adrenoceptor","drug_class":"Corticosteroid [EPC]","quality_score":60,"revenue":null,"mechanism":"Budesonide reduces inflammation, while formoterol relaxes airway muscles, together improving symptoms of COPD and asthma."},{"drug_id":"salmeterol","indication_name":"Asthma Treatment","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SALMETEROL","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor, beta2-adrenoceptors","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Fluticasone propionate reduces inflammation, while salmeterol relaxes bronchial muscles and inhibits mediator release."},{"drug_id":"salmeterol","indication_name":"Asthma Not Adequately Controlled","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SALMETEROL","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor, beta2-adrenoceptors","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Fluticasone propionate reduces inflammation, while salmeterol relaxes bronchial muscles and inhibits mediator release."},{"drug_id":"tezepelumab","indication_name":"Severe Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tezspire","generic_name":"TEZEPELUMAB","company_name":"AstraZeneca / Amgen","drug_phase":"marketed","molecular_target":"","drug_class":"Thymic Stromal Lymphopoietin Blocker [EPC]","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"alvesco","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Omnaris","generic_name":"Alvesco","company_name":"Takeda Gmbh","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"ciclesonide","quality_score":63,"revenue":null,"mechanism":"Omnaris works by activating the glucocorticoid receptor to reduce inflammation in the airways."},{"drug_id":"ciclesonide","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Omnaris","generic_name":"CICLESONIDE","company_name":"Covis","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"ciclesonide","quality_score":63,"revenue":null,"mechanism":"Omnaris works by binding to the glucocorticoid receptor, which then reduces inflammation in the airways."},{"drug_id":"cromoglicate","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cromoglicate","company_name":"LEO Pharma","drug_phase":"discontinued","molecular_target":"Protein S100-P, G-protein coupled receptor 35, Taste receptor type 2 member 20","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"umec","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"UMEC","company_name":"Glaxo Grp England","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3","drug_class":"","quality_score":null,"revenue":null,"mechanism":"UmeC is a small molecule drug that works by interacting with a specific target in the body."},{"drug_id":"cortisol","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cortisol","company_name":"University of Zurich","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"reproterol","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epiferol","generic_name":"REPROTEROL","company_name":"","drug_phase":"phase_2","molecular_target":"Beta-2 adrenergic receptor","drug_class":"reproterol","quality_score":null,"revenue":null,"mechanism":"Epiferol works by stimulating the beta-2 adrenergic receptor to increase the concentration of cyclic AMP, leading to bronchodilation."},{"drug_id":"hydrocortisone-succinate","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Solu-Cortef","generic_name":"hydrocortisone succinate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"depemokimab","indication_name":"severe asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Exdensur","generic_name":"DEPEMOKIMAB","company_name":"Glaxosmithkline Llc","drug_phase":"marketed","molecular_target":"Histamine","drug_class":"","quality_score":51,"revenue":null,"mechanism":"Exdensur works by binding to histamine, preventing it from interacting with its receptors and reducing inflammation and airway constriction."},{"drug_id":"depemokimab","indication_name":"status asthmaticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Exdensur","generic_name":"DEPEMOKIMAB","company_name":"Glaxosmithkline Llc","drug_phase":"marketed","molecular_target":"Histamine","drug_class":"","quality_score":51,"revenue":null,"mechanism":"Exdensur works by binding to histamine, preventing it from interacting with its receptors and reducing inflammation and airway constriction."},{"drug_id":"ibudilast","indication_name":"Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ketas","generic_name":"IBUDILAST","company_name":"Kyorin Pharmaceutical","drug_phase":"marketed","molecular_target":"cAMP-specific 3',5'-cyclic phosphodiesterase 4A","drug_class":"ibudilast","quality_score":17,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":172,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03000491","title":"Learning Health System for Asthma","phase":"","overall_status":"COMPLETED","enrollment_count":750000,"lead_sponsor_name":"University of Edinburgh","has_results":false},{"nct_id":"NCT04905420","title":"The Impact of PCCM on Healthcare Among Asthma or Chronic Obstructive Pulmonary Disease (COPD) or Asthma-COPD Overlap Patients","phase":"","overall_status":"COMPLETED","enrollment_count":288538,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06668974","title":"Causal Associations Between Allergic Rhinitis and Asthma","phase":"","overall_status":"COMPLETED","enrollment_count":239607,"lead_sponsor_name":"Zhibin Xu","has_results":false},{"nct_id":"NCT03330301","title":"D-tecting Disease - From Exposure to Vitamin D During Critical Periods of Life","phase":"","overall_status":"COMPLETED","enrollment_count":222776,"lead_sponsor_name":"Bispebjerg Hospital","has_results":false},{"nct_id":"NCT07317141","title":"The Effectiveness of Early Immunisation With Nirsevimab on Preschool Wheezing in France, Based on an Analysis of Data From the French Health System Database.","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":218000,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT03987633","title":"EMPOWER-1: A Multi-site Clinical Cohort Research Study to Reduce Health Inequality","phase":"","overall_status":"RECRUITING","enrollment_count":200000,"lead_sponsor_name":"Future Genetics Limited","has_results":false},{"nct_id":"NCT03106727","title":"Evaluating the Impact of a Community Health Worker Program in Neno, Malawi","phase":"NA","overall_status":"COMPLETED","enrollment_count":122395,"lead_sponsor_name":"Partners in Health","has_results":false},{"nct_id":"NCT03692676","title":"Characteristics of Pts Initiating Spiriva Respimat in Asthma","phase":"","overall_status":"COMPLETED","enrollment_count":116133,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT03285230","title":"The French E3N Prospective Cohort Study","phase":"","overall_status":"UNKNOWN","enrollment_count":100000,"lead_sponsor_name":"Institut National de la Santé Et de la Recherche Médicale, France","has_results":false},{"nct_id":"NCT01399411","title":"Agricultural Health Study Follow-up","phase":"","overall_status":"COMPLETED","enrollment_count":89656,"lead_sponsor_name":"National Institute of Environmental Health Sciences (NIEHS)","has_results":false},{"nct_id":"NCT07436104","title":"Mortality Control Program for Economically Productive Age Group in Tribal Area of Melghat.","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":72564,"lead_sponsor_name":"MAHAN Trust","has_results":false},{"nct_id":"NCT06903897","title":"Social Needs Screening and Chronic Diseases Study (WE CARE)","phase":"NA","overall_status":"RECRUITING","enrollment_count":68000,"lead_sponsor_name":"University of Massachusetts, Worcester","has_results":false},{"nct_id":"NCT04892732","title":"Replication of the D58 Asthma Trial in Healthcare Claims Data","phase":"","overall_status":"COMPLETED","enrollment_count":66581,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT00342030","title":"Dietary and Genetic Factors in Asthma & Chronic Bronchitis in a Cohort of Chinese Singaporeans","phase":"","overall_status":"COMPLETED","enrollment_count":63257,"lead_sponsor_name":"National Institute of Environmental Health Sciences (NIEHS)","has_results":false},{"nct_id":"NCT06488703","title":"Retrospective Analysis of Systemic Glucocorticoid Mediated Long-term Effects, Patient Pathways and Economic Burden Across Multiple Indications","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":52000,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT04239521","title":"The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata","phase":"","overall_status":"COMPLETED","enrollment_count":51955,"lead_sponsor_name":"Momentum Data","has_results":false},{"nct_id":"NCT05457855","title":"Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Montelukast vs Fluticasone","phase":"","overall_status":"COMPLETED","enrollment_count":51533,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":true},{"nct_id":"NCT06837584","title":"Control and Treatment of Outpatient Children With Asthma","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":42000,"lead_sponsor_name":"Beijing Children's Hospital","has_results":false},{"nct_id":"NCT03963141","title":"Retrospective Analysis to Describe Patient Profiles, Current Treatment Patterns and Economic Burden for Asthma Patients in UAE. A Descriptive Analysis of the Asthma Patient Population in the Emirate of Dubai With Respect to Healthcare Resource Utilization, Costs, and Asthma-related Treatment Pattern","phase":"","overall_status":"COMPLETED","enrollment_count":40541,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03840928","title":"PatientSpot Formerly Known as ArthritisPower","phase":"","overall_status":"UNKNOWN","enrollment_count":40000,"lead_sponsor_name":"Global Healthy Living Foundation","has_results":false},{"nct_id":"NCT04684836","title":"Comparative Effectiveness of Telemedicine in Primary Care","phase":"","overall_status":"COMPLETED","enrollment_count":33100,"lead_sponsor_name":"Weill Medical College of Cornell University","has_results":true},{"nct_id":"NCT07532564","title":"Risk Factors, Costs, and Impacts of ED Boarding","phase":"","overall_status":"COMPLETED","enrollment_count":30486,"lead_sponsor_name":"University of Maryland, Baltimore","has_results":false},{"nct_id":"NCT06512142","title":"Using Artificial Intelligence for the Detection of Respiratory Diseases Associated With Pollution","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"University of Medicine and Pharmacy \"Victor Babes\" Timisoara","has_results":false},{"nct_id":"NCT00341237","title":"Personalized Environment and Genes Study","phase":"","overall_status":"RECRUITING","enrollment_count":25000,"lead_sponsor_name":"National Institute of Environmental Health Sciences (NIEHS)","has_results":false},{"nct_id":"NCT06279078","title":"Long-term Effect of Steroid on Metabolic Diseases in Asthmatics","phase":"","overall_status":"COMPLETED","enrollment_count":19968,"lead_sponsor_name":"Ajou University School of Medicine","has_results":false},{"nct_id":"NCT05157087","title":"XOLAIR (Omalizumab) Outcomes in Pediatric Allergic Asthma Patients in the United States","phase":"","overall_status":"COMPLETED","enrollment_count":16246,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03945968","title":"The Role of Concomitant Diseases in Postoperative Complications Risk Stratification.","phase":"","overall_status":"RECRUITING","enrollment_count":16000,"lead_sponsor_name":"Russian Federation of Anesthesiologists and Reanimatologists","has_results":false},{"nct_id":"NCT04991805","title":"Descriptive Study of the Incidence of Malignancy in Severe Asthma Patients Receiving Benralizumab and Other Biologic Therapy, a Post Authorization Safety Study","phase":"","overall_status":"COMPLETED","enrollment_count":14000,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04715945","title":"Southampton Women's Survey","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":12583,"lead_sponsor_name":"University of Southampton","has_results":false},{"nct_id":"NCT02760329","title":"Observational Study of Obstructive Lung Disease (NOVELTY)","phase":"","overall_status":"COMPLETED","enrollment_count":12255,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03175536","title":"Asthma in Families Facing Out-of-pocket Requirements With Deductibles","phase":"","overall_status":"COMPLETED","enrollment_count":12238,"lead_sponsor_name":"Harvard Pilgrim Health Care","has_results":true},{"nct_id":"NCT01475721","title":"SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":11751,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01471340","title":"A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":11744,"lead_sponsor_name":"Organon and Co","has_results":true},{"nct_id":"NCT06685315","title":"Research on the Characteristics of Chronic Airway Diseases (asthma, COPD)","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":10545,"lead_sponsor_name":"Henan University of Traditional Chinese Medicine","has_results":false},{"nct_id":"NCT04892758","title":"Replication of the P04334 Asthma Trial in Healthcare Claims Data","phase":"","overall_status":"COMPLETED","enrollment_count":10288,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT06732414","title":"A Biorepository of Multiple Allergic Diseases (MADREP) With Longitudinal Follow-Up","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT06528418","title":"Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"ChromX Health","has_results":false},{"nct_id":"NCT07523724","title":"Screening and Management of Adults With Asthma and Allergic Diseases","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":9666,"lead_sponsor_name":"Beijing Hospital","has_results":false},{"nct_id":"NCT05952999","title":"Analysis of the Virtual Acute Care at Home Experience","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":9654,"lead_sponsor_name":"OSF Healthcare System","has_results":false},{"nct_id":"NCT01688986","title":"Environmental Polymorphisms Registry Health and Exposures Survey","phase":"","overall_status":"COMPLETED","enrollment_count":9000,"lead_sponsor_name":"National Institute of Environmental Health Sciences (NIEHS)","has_results":false},{"nct_id":"NCT06521229","title":"Clinical& Demographic Profiles of patIents With unControllEd Asthma in Russia: Multi-center oBsErvational ReGistry Study","phase":"","overall_status":"RECRUITING","enrollment_count":9000,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03857178","title":"SABINA INTERNATIONAL","phase":"","overall_status":"COMPLETED","enrollment_count":8617,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04550780","title":"Nation-wide Health Resource Consumption and Costs Associated With Mepolizumab","phase":"","overall_status":"COMPLETED","enrollment_count":7938,"lead_sponsor_name":"University Hospital, Montpellier","has_results":false},{"nct_id":"NCT03964220","title":"Impact of Tiotropium Add-on Therapy in Patients With Asthma","phase":"","overall_status":"COMPLETED","enrollment_count":7857,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT03248869","title":"Asthma Mobile Health Application 2.0","phase":"NA","overall_status":"COMPLETED","enrollment_count":7752,"lead_sponsor_name":"Icahn School of Medicine at Mount Sinai","has_results":false},{"nct_id":"NCT06457009","title":"Impact of Multi-Component Intervention on Suspected Asthma Population","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":7400,"lead_sponsor_name":"Peking Union Medical College","has_results":false},{"nct_id":"NCT03608566","title":"Russian Severe Asthma Registry","phase":"","overall_status":"UNKNOWN","enrollment_count":7000,"lead_sponsor_name":"Interregional Public Organization, Russian Respiratory Society","has_results":false},{"nct_id":"NCT04057521","title":"Coordinated HEalthcare for Complex Kids","phase":"NA","overall_status":"COMPLETED","enrollment_count":6259,"lead_sponsor_name":"University of Illinois at Chicago","has_results":false},{"nct_id":"NCT01462344","title":"6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":6250,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT06419400","title":"A Research Study to Explore the Impact of GP Support Via Text Messages to Patients With Asthma and/or COPD","phase":"NA","overall_status":"COMPLETED","enrollment_count":6053,"lead_sponsor_name":"Accurx","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}